Neurology in New York

Aktina Medical Corp. is a radiation oncology equipment and services company specializing in stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), and precision localization and immobilization solutions for LINAC (linear accelerator) treatments. The company manufactures and distributes patient immobilization systems, respiratory compression devices, cone collimators for small-field radiation delivery, and quality assurance systems for radiation therapy equipment. Primary product lines include the positionPRO modular immobilization system (offering pitch and roll correction for cranial, cervical spine, and head/neck treatments), SBRT systems, Elekta small-field circular cones, respiratory compression belts, and the isoPoint machine vision platform for LINAC isocenter optimization and calibration. Aktina also provides medical physics consultation services, diagnostic and therapeutic physics support, and quality assurance solutions including the SpiroCheck Duo system for active breathing control (ABC) validation. The company serves radiation oncology departments, cancer centers, and tertiary care hospitals requiring high-precision patient positioning and LINAC calibration for intracranial, head/neck, and body-based radiation treatments. Products are designed for compatibility with Elekta LINAC platforms and emphasize both treatment precision and patient comfort through innovative immobilization technology.

Precision Neuroscience

Precision Neuroscience is a neurotechnology company founded in 2021 that specializes in developing minimally invasive brain-computer interfaces (BCIs) aimed at treating neurological disorders. The company focuses on high-resolution, non-penetrating cortical surface arrays that record brain signals without damaging tissue. Its flagship product, the Layer 7 Cortical Interface, is a thin-film microelectrode array designed to capture detailed brain activity, enabling thought-controlled actions. Co-founded by neurosurgeon Ben Rapoport and business builder Michael Mager, Precision Neuroscience has expanded its team and established its own manufacturing facility. The company has conducted human clinical trials and received FDA clearance for its core device, with commercial products expected soon. Precision's mission is to create safe, removable BCIs that enhance communication and independence for individuals with severe conditions such as paralysis and speech deficits. The company collaborates with notable institutions like the Rockefeller Neuroscience Institute and Mount Sinai Health System to advance its clinical development efforts.

GrayMatters Health develops Prism, an interventional psychiatry software platform that leverages fMRI-informed digital biomarkers and EEG neurofeedback to deliver personalized psychiatric care. The company's core technology uses real-time brain activity monitoring via EEG sensors to help patients self-regulate neural patterns associated with mental health conditions. Prism offers clinically validated protocols for PTSD (utilizing amygdala-based biomarkers) and Major Depressive Disorder (targeting ventral striatum reward-system activity). The platform integrates into clinical workflows, allowing technicians to administer sessions under clinician supervision, optimizing operational efficiency. GrayMatters emphasizes evidence-based design with published clinical studies demonstrating efficacy in symptom reduction and improved patient outcomes. The company provides comprehensive support including onsite installation, staff training, and ongoing technical assistance. Prism represents a bridge between neuroscience research and accessible psychiatric practice, enabling clinicians to augment standard-of-care therapies with objective, brain-derived biomarker data. The technology is designed for clinic deployment with minimal storage footprint and seamless integration into existing treatment protocols.

Neurodynamics Inc. is a New York–based neurosurgical device manufacturer founded in 1987, specializing in stereotactically guided catheter placement instruments for ventricular access and ventriculostomy procedures. The company's primary product is The Ghajar Guide® System, a ventricular access device that enables accurate catheter placement into the brain ventricles for cerebrospinal fluid (CSF) drainage and intracranial pressure (ICP) reduction and control. The device is designed to facilitate first-pass catheter placement and reduce complications associated with freehand ventricular catheterization. The Ghajar Guide® system is indicated for use in traumatic brain injury (TBI), hydrocephalus, and other conditions requiring emergency ventricular drainage and ICP monitoring. All products carry FDA 510(k) marketing approval. The company serves neurosurgeons and trauma centers in the United States and internationally, offering both direct sales and distribution channels. Neurodynamics manufactures and supplies specialized surgical instruments and devices for cranial neurosurgery and operates from a New York facility.

MEDIVIS develops FDA-cleared augmented reality (AR) and surgical navigation software for intraoperative guidance and preoperative planning. The company's flagship product, SurgicalAR, transforms 2D cross-sectional imaging (CT, MRI) into high-fidelity 3D visualizations with real-time surgical navigation and spatial computing capabilities. Primary offerings include: Spine Navigation (FDA-cleared for open and minimally invasive spine procedures), Cranial Navigation (FDA-cleared for EVDs, subdural evacuations, and craniotomies), and Prostate Navigation (research-stage for biopsies and ablations). SurgicalAR features on-premise IT infrastructure with certified gold-standard security, infrared instrument tracking by specialty, photorealistic 3D renderings, model segmentation, livestream imaging to virtual monitors, spatial hand and voice interactions, and an integrated AI agent (Maia, coming soon). Hardware platforms include Medivis PRO (27" touch monitor, 4K graphics, NVIDIA GPU for operating rooms), Medivis CORE (17" portable workstation for ICUs and clinics), and Medivis VIEWER (spatial computing visualization for planning). The company has deployed across 40+ hospitals and medical schools, with 2,000+ surgeries performed using SurgicalAR. Regulatory clearances include FDA 510(k) clearance for spine and cranial modules, CE marking, and Korea FDA clearance. The technology integrates with existing surgical workflows and imaging systems, supporting neurosurgery, orthopedic, and urological specialties. Recognized by TIME Magazine (Best Inventions 2023), Fast Company (Most Innovative 2024), and as Edison Award finalist (2024).

Image Monitoring USA Inc is a Buffalo, NY-based distributor and supplier of advanced transcranial Doppler (TCD) and peripheral vascular testing systems. The company specializes in non-invasive vascular diagnostic equipment serving neurologists, radiologists, cardiologists, intensivists, neonatologists, anesthesiologists, stroke specialists, and researchers. Primary product lines include the Dolphin IQ and Dolphin 4D TCD systems with robotic headset options (XF Robotic Headset) for short- and long-term cerebrovascular monitoring, and the Falcon series of physiologic vascular testing platforms (Falcon PRO, Falcon Quad PVD, and Falcon Xpress variants FX5–FX11) for ankle-brachial index (ABI) and toe-brachial index (TBI) testing in hospital, clinic, and mobile settings. The Falcon Xpress line includes models optimized for office, mobile, and laptop-based configurations. The company maintains a team of seasoned professionals across the United States to support system selection, installation, and ongoing technical service. Equipment is marketed for use in vascular laboratories, neurology departments, ICUs, NICUs, operating rooms, and outpatient clinics. Regulatory certifications and manufacturing details are not explicitly stated on the website. The company emphasizes user-friendly interfaces, customizable workflows, reliable uptime, and dedicated customer support. Operating hours are Monday–Friday, 8:00 AM–4:30 PM EST.

Axon Therapies, Inc. (registered trade name of Axon Vascular, Inc.) is a clinical-stage medtech company developing the Satera Ablation System for treatment of heart failure with preserved ejection fraction (HFpEF). The company's proprietary SAVM (Splanchnic Ablation for Volume Management) procedure uses an ablation catheter to target the greater splanchnic nerve via percutaneous venous access, aiming to reduce sympathetic nervous system activity and normalize volume balance in heart failure patients. The minimally invasive, implant-free outpatient procedure typically takes under one hour. Axon's lead investigational device is the Axon Ablation Catheter, designed to deliver targeted ablation therapy to block sympathetic nerve signals and reverse cardiac congestion. The company is currently conducting the Rebalance-HF clinical trial (NCT04592445), which demonstrated 12-month results showing reduced pulmonary capillary wedge pressure (PCWP) by 18 mmHg versus sham, improved quality of life (KCCQ +17), and increased six-minute walk distance (+49 meters). The device is investigational and not yet approved for clinical use in any geography. Axon is backed by institutional investors including Deerfield Management, Action Potential Venture Capital (GSK's bioelectronic medicines fund), and has assembled an experienced leadership team with deep medtech commercialization expertise and clinical advisory board comprising leading cardiologists from Mayo Clinic, Duke University, Northwestern University, Mount Sinai, and the Medical University of South Carolina. The company maintains offices in New York and Altrincham, United Kingdom.

Positrigo AG is a Swiss medical imaging company specializing in dedicated brain Positron Emission Tomography (PET) systems. The company manufactures the NeuroLF, an ultra-compact, fully integrated brain PET scanner designed to make functional neuroimaging accessible and affordable for precision medicine applications. The NeuroLF system is particularly focused on early diagnosis of neurodegenerative diseases, including Alzheimer's disease and other dementia-related disorders. The company has achieved FDA clearance (July 2024) and CE Mark (October 2024) for its NeuroLF system, enabling commercialization in the US and Europe. Positrigo holds ISO 13485:2016 certification, demonstrating compliance with medical device quality management standards. The company manufactures and distributes its systems through a network of international distributors across Europe, the US, and other regions. Recent deployments include installations at The Neuron Clinic (first US outpatient neurology clinic), Beverly Hills Medical Imaging, University Hospital of Genoa (Italy), and LMU Hospital Munich (Germany). Positrigo operates a US subsidiary established in 2023 and launched the BrainPET Accelerator program in the US to support clinical adoption. The company is backed by significant venture funding and has received grants from Innosuisse and the European Innovation Council (EIC Fund).

Oculogica Inc. is a woman-owned medical device company specializing in non-invasive eye-tracking diagnostic technology for objective concussion assessment. The flagship product, EyeBOX®, is FDA-cleared to aid in concussion diagnosis by measuring ocular motor abnormalities caused by cranial nerve impairment. The test is completed in under four minutes and delivers an objective "BOX score" within ten seconds, eliminating the need for baseline testing. Clinically validated through 16 peer-reviewed studies, EyeBOX® provides objective neurological assessment across patient ages 5–67 and is reimbursable. The technology serves sports medicine, veteran care, accident clinics, therapeutic clinics, and eye clinics. Oculogica's proprietary algorithms ensure diagnostic consistency across healthcare settings and improve communication between patients, families, and providers.

Netech Corporation is a US-based manufacturer of biomedical test equipment and patient simulators for medical device validation and clinical training. Founded over 33 years ago, the company specializes in portable, easy-to-use testing instruments designed for hospital clinical engineering, biomedical maintenance, device manufacturers, and training institutions. Product categories include patient simulators (ECG, EEG, SpO2, pacemaker), defibrillator analyzers, infusion pump analyzers, electrical safety analyzers, pressure meters, and gas flow meters. The MiniSim product line offers compact, modular waveform generators for testing cardiac monitors, EEG recorders, and multi-parameter patient monitoring systems. The EXPMT 2000 External Pacemaker Analyzer is designed for atrial, ventricular, and transcutaneous pacemaker testing. All products are manufactured in the USA. Netech serves clinical engineering departments, biomedical equipment manufacturers, healthcare training centers, and medical device testing laboratories. The company emphasizes quality, reliability, and value in regulatory and performance testing workflows. Equipment is used for device validation, preventive maintenance, troubleshooting, and competency-based training. Netech's offerings support compliance with medical device testing standards and clinical engineering protocols.

Fisher-Wallace Laboratories manufactures wearable transcranial electrical stimulation (tES) devices for neuropsychiatric conditions. The company's flagship product is OAK, a patent-pending, low-dose electrical brain stimulation headset designed to treat mood, sleep, and cognitive disorders with a 20-minute daily protocol requiring no Bluetooth or smartphone connectivity. OAK is currently in FDA clearance pathway with anticipated approval for anxiety treatment in Summer 2026, followed by depression and insomnia indications in 2027. The device has been studied in over 1,500 clinical trial participants and demonstrates safety and efficacy for Major Depressive Disorder, chronic insomnia, PTSD, Bipolar Depression, Parkinson's Disease, and Substance Use Disorder. A legacy Version 1.0 device, distributed under an FDA pathway that closed in 2019, remains in use by approximately 60,000 patients for maintenance and cognitive support. Research devices are currently deployed at the U.S. Department of Veterans Affairs. The company was co-founded by Chip Fisher and the late Dr. Martin Wallace, with Kelly Roman joining as co-founder and CEO. The company is backed by equity crowdfunding ($11 million raised from customers beginning in 2019) and seeks institutional investors for scaling across government, telemedicine, employer, and medical center channels. Clinical advisors include faculty from Harvard Medical School and Massachusetts General Hospital.

Spark Neuro is a digital health company specializing in dementia diagnosis and care optimization. The company addresses a critical clinical gap: nearly 50% of dementia cases in the United States go undiagnosed, with primary care physicians lacking sufficient time and neurological expertise to conduct thorough cognitive assessments. Spark Neuro's platform leverages clinical decision-support technology to enable earlier dementia detection, identification of high-risk patients, and streamlined care pathways. The solution targets health plans, health systems, and primary care networks. Spark Neuro works with major healthcare organizations including Mayo Clinic, Johns Hopkins Medicine, Humana, and the National Institutes of Health, indicating regulatory credibility and clinical validation. The platform reduces provider burden by supporting PCPs in cognitive screening and assessment workflows, helping close diagnostic gaps while improving patient outcomes through early intervention. The company's value proposition centers on lowering undiagnosed dementia rates, improving care coordination between primary care and neurology specialists, and reducing long-term costs associated with late-stage dementia management.

Kinvent develops connected biomechanical assessment devices and software for rehabilitation, sports performance, clinical diagnosis, and research. The company specializes in real-time measurement of strength, balance, mobility, and neuromuscular function through a suite of portable, sensor-based products. Their device portfolio includes force plates (K-Deltas, K-Deltas XL, 3D Deltas, K-Force Plates), handheld and fixed dynamometers (K-Push, K-Pull, K-Grip, K-Bubble), motion sensors (K-Move for goniometry, K-Power for gait and speed analysis), and surface EMG sensors (K-Myo). All devices integrate with a HIPAA-compliant software platform for data capture, analysis, and patient progress tracking. Kinvent targets physical therapists, sports performance coaches, physicians, orthopedic specialists, and researchers. The platform supports objective assessments for return-to-sport testing, rehabilitation outcome measurement, injury prevention, and performance optimization. The company serves professional sports teams (including MLB's Cleveland Guardians), academic medical centers (Hospital for Special Surgery, Weill Cornell Medicine, Stanford Health Care), and research institutions. Products are used for ACL rehabilitation, lower-back pain assessment, ankle sprain management, gait analysis, vertical jump assessment, grip strength evaluation, and neuromuscular symmetry testing.

NeuralPulse Ltd. is a medical device company developing an adaptive neuromodulation therapy for drug-resistant epilepsy. The company's core product is an intracranially implantable neuromodulation device that uses a three-stage approach: probing the brain with electrical pulses to assess neural state, predicting seizure likelihood based on brain response patterns, and preventing seizures through therapeutic electrical stimulation. The technology represents a paradigm shift from passive seizure detection to active predictive neuromodulation. The company completed first-in-human clinical trials at King's College Hospital, London, demonstrating in eight drug-resistant epilepsy patients that active probing significantly improves seizure prediction accuracy compared to passive monitoring techniques and that tracking brain response to electrical stimulation is safe, ethically permissible, and well-tolerated. The founding team comprises leading neuroscientists and clinicians from King's College London, including the Chief Executive Officer (research fellow in health informatics and biostatistics), Chief Medical Officer (Professor of Epilepsy), and Chief Scientific Officer (Senior Lecturer in Clinical Neurophysiology and Honorary Clinical Neurology Consultant). Academic advisors include engineering and biomedical device experts from Oxford University and University of Washington. The company has received recognition including the Best Innovation prize at the London Institute for Healthcare Engineering Showcase (February 2025) and completed the inaugural King's MedTech Accelerator programme. Partnerships include King's College London, King's Health Partners, King's College Hospital, and CorTec (neuromodulation device manufacturer). The company is positioned within the emerging field of closed-loop neuromodulation for seizure management, targeting patients with epilepsy unresponsive to pharmaceutical interventions.

Evoke by Firefly Neuro (formerly Evoke Neuroscience) is a healthcare technology company specializing in computational EEG (electroencephalography) systems for objective brain health assessment and early diagnosis of cognitive impairment. The company's flagship product, the evoke® Brain Health System, is an FDA-cleared Class II medical device that uses quantitative EEG (qEEG) and event-related potential (ERP) recordings to evaluate neurophysiology biomarkers in clinical settings. The system enables primary care and specialty physicians to assess cognitive function in-office in under one hour, helping identify treatable conditions such as dementia, memory loss, depression, and ADHD. With over 191,000 assessments performed and 2 billion data points collected, Evoke serves healthcare providers and pharmaceutical companies in CNS drug development. The company provides hardware, software, clinician training, and ongoing clinical education to facilitate integration into existing practices.

DIXI Medical is a specialized neurosurgical device manufacturer with over 50 years of expertise in stereotactic electroencephalography (SEEG) systems and functional neurosurgery. The company develops high-precision intracerebral electrodes, intraoperative neurophysiological monitoring systems, and stereotactic implantation accessories for epilepsy diagnosis, treatment, and brain research applications. Core product lines include MICRODEEP® SEEG electrodes (sterile, single-use with up to 18 contacts and 0.8 mm diameter for deep brain exploration and thermocoagulation), MICRODEEP® Micro-Macro electrodes (for simultaneous multi-scale neuronal recording bridging clinical and research use), and Cortical IOM electrodes for intraoperative real-time cortical monitoring and stimulation. The company also manufactures dedicated stereotactic implantation instruments and accessories. DIXI Medical serves epilepsy centers and functional neurosurgery programs in over 40 countries and supports SEEG training and research initiatives globally. Manufacturing capabilities include microtechnical precision engineering, sterilization, and quality assurance aligned with medical device standards. The company emphasizes clinical collaboration with neurosurgeons, neurologists, and researchers, with field-based clinical support teams and ongoing investment in training programs for healthcare professionals. Products are designed for compatibility with robotic stereotactic systems and are used in both surgical and research settings.

Anschel Technology Inc. manufactures the SightSaver™, an FDA-approved and patented device for eliciting visual evoked potentials (VEPs) during intraoperative monitoring. The device is designed to prevent post-operative visual loss (POVL)—a serious complication affecting several thousand patients annually in the United States following non-ocular surgical procedures such as spine surgery. The SightSaver™ addresses critical gaps in existing visual stimulation approaches by providing a hygienic, safe, comfortable, and reliable alternative to low-quality, non-hygienic, and unreliable legacy stimulators. The company was founded in 2011 by Dr. David Anschel, a board-certified neurologist and clinical neurophysiologist with extensive academic credentials and research background. The SightSaver products enable perioperative vision risk management through real-time intraoperative visual monitoring, supporting surgical teams in detecting and mitigating vision loss during high-risk procedures.

Firefly Neuroscience is an FDA-cleared neurodiagnostic software platform company specializing in objective brain health assessment and early detection of neurological and psychiatric conditions. The company's flagship product, Evoke™ System, combines quantitative EEG (qEEG) and event-related potentials (ERP) analysis with proprietary AI and machine learning to translate complex brain signals into clinically actionable insights. Built on a proprietary database of over 191,000 EEG and ERP sessions from individuals aged 12–85, Evoke™ enables clinicians to identify deviations in brain function, differentiate overlapping conditions (depression, anxiety, ADHD, concussion, cognitive decline, neurodegenerative disorders), and track treatment response with precision. The platform delivers age-matched normative comparisons and cloud-based reporting to support earlier diagnosis, more targeted treatment planning, and personalized care protocols. Firefly serves healthcare practitioners seeking measurable, data-driven neurological assessment and supports CNS drug developers through biomarker development and companion diagnostic collaborations.

FONAR Corp. is a pioneer and manufacturer of Magnetic Resonance Imaging (MRI) systems, specifically known for the invention and development of the FONAR UPRIGHT® Multi-Position™ MRI scanner. Unlike conventional MRI systems that can only image patients in the supine (lying down) position, FONAR's proprietary technology enables multi-positional scanning—allowing patients to be imaged while sitting, standing, bending, flexing, extending, or lying down. This capability is clinically significant for identifying position-dependent pathology, particularly in spinal and neurological conditions, as it allows physicians to visualize the full extent of disk herniation, vertebral motion, and other dynamic pathologies that may only manifest in weight-bearing or functional positions. The UPRIGHT® MRI utilizes a unique vertically oriented magnet configuration with opposing poles and a motorized patient bed capable of rotating from recumbent to fully upright. FONAR also offers enhanced patient comfort for claustrophobic and bariatric patients. The company conducts ongoing research in cerebrospinal fluid (CSF) flow dynamics, correlated slice protocols, multiple sclerosis diagnostics, and scoliosis screening using advanced MRI videography and quantitative imaging techniques. Founded by Dr. Raymond V. Damadian, who is credited with the discovery and development of MRI technology, FONAR holds foundational patents in MRI and has received recognition including the National Inventors Hall of Fame designation and the 2007 Inventor of the Year award for the UPRIGHT® MRI system. The company operates FONAR diagnostic imaging centers through its Health Management Company of America (HMCA) subsidiary, providing both equipment manufacturing and clinical imaging services.

BioSignal is a neurodiagnostic company specializing in functional brain assessment via portable EEG technology. The company's FDA-approved microEEG® solution is a miniature, wireless clinical platform enabling rapid electroencephalogram (EEG) recording with cloud-based remote interpretation. BioSignal serves traditional neurology settings (epilepsy centers, sleep labs, neurology departments, ICUs) and expands brain function assessment into novel environments including emergency departments, NICUs, physician offices, ambulances, and home care. The platform supports sports concussion management, traumatic brain injury assessment, routine EEG monitoring, and STAT EEG capabilities. Applications span clinical neurology, emergency medicine, pediatric critical care, sleep medicine, sports medicine, and home sleep monitoring. The solution combines hardware portability with interpretive software to enable rapid assessment and telemedicine-capable EEG interpretation.

CEIBA Health Technologies is an AI-powered healthcare technology platform specializing in virtual clinical care and medical device connectivity solutions. The company delivers an integrated Enterprise Suite with four core capabilities: (1) IoMT Interoperability—featuring a plug-and-play IoMT Box with 1,000+ pre-installed device drivers supporting 20+ EHR integrations; (2) Continuous Monitoring—delivering real-time telemetry dashboards for patient monitors, ventilators, infusion pumps, blood gas analyzers, and EEG machines across ICU, med-surge, LTACH, and SNF settings; (3) Decision Support & Workflow—providing actionable clinical insights and operational dashboards; and (4) Virtual Clinical Care—a telehealth platform enabling multi-specialty consultations, remote rounding, and acute care at home. CEIBA's protocol-agnostic architecture supports HL7, FHIR, JSON, and XML with enterprise-grade security, encrypted data transfer, and full mobile functionality. The platform is designed for rapid deployment (days vs. months) and serves hospitals and health systems in the US and internationally.

Kerber USA Inc. manufactures SunPowerLED photobiomodulation (PBM) therapy devices using red and near-infrared light technology for pain relief, inflammation reduction, and tissue healing. The company designs medical-grade LED light therapy devices for professional and home use, serving dentists, chiropractors, physiotherapists, and wellness centers. Their patent-pending cooling system enables extended skin contact and increased light penetration. Products include handheld Palm devices (660nm, 810nm, 1050nm wavelengths), canopy systems for larger body areas, and transcranial PBM helmets for neurological applications. Clinically researched and documented with over 100 million patient treatments globally, SunPowerLED devices are FDA Class 2 compliant and used across professional healthcare and personal wellness settings.